Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any inherited bleeding disorder, platelet-type in which the cause of the disease is a mutation in the SLFN14 gene.
Features include always present findings: Low platelet count (thrombocytopenia). 4 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 1 | Low platelet count (thrombocytopenia) |
SLFN14 function has not been fully characterized.
Platelet-type bleeding disorder 20 has been associated with mutations in the SLFN14 gene on chromosome 17.
Genetic testing for SLFN14 is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for platelet-type bleeding disorder 20 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for platelet-type bleeding disorder 20.
10 publications have been identified in PubMed for platelet-type bleeding disorder 20. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (20%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 5 | 50% |
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 4:32 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
2 |
20% |
Testing and diagnosis research | 1 | 10% |
Patient case studies | 1 | 10% |
Disease patterns and progression | 1 | 10% |
Wu J (2026). [PMID: 41503871](https://pubmed.ncbi.nlm.nih.gov/41503871/). *J Cell Mol Med*. [Review / Meta-Analysis]
Luo M (2025). [PMID: 40464691](https://pubmed.ncbi.nlm.nih.gov/40464691/). *Nucleic Acids Res*. [Basic Science / Preclinical]
Sánchez-Fuentes A (2025). [PMID: 40563486](https://pubmed.ncbi.nlm.nih.gov/40563486/). *Biomolecules*. [Review / Meta-Analysis]
Xie H (2025). [PMID: 40510593](https://pubmed.ncbi.nlm.nih.gov/40510593/). *Mol Ther Nucleic Acids*. [Basic Science / Preclinical]
Van Riper J (2025). [PMID: 40592880](https://pubmed.ncbi.nlm.nih.gov/40592880/). *Nat Commun*. [Basic Science / Preclinical]
Sakamoto A (2025). [PMID: 40954090](https://pubmed.ncbi.nlm.nih.gov/40954090/). *Br J Haematol*. [Epidemiology / Natural History]
Chen SM (2025). [PMID: 41406233](https://pubmed.ncbi.nlm.nih.gov/41406233/). *Sci Adv*. [Basic Science / Preclinical]
Tanaka Y (2024). [PMID: 38890442](https://pubmed.ncbi.nlm.nih.gov/38890442/). *Sci Rep*. [Basic Science / Preclinical]
Niehues T (2024). [PMID: 39381601](https://pubmed.ncbi.nlm.nih.gov/39381601/). *Allergol Select*. [Diagnostic / Biomarker]
Hernandez RA (2024). [PMID: 38710235](https://pubmed.ncbi.nlm.nih.gov/38710235/). *J Allergy Clin Immunol*. [Case Report / Case Series]